Skip to main content
Advertisement
Browse Subject Areas
?

Click through the PLOS taxonomy to find articles in your field.

For more information about PLOS Subject Areas, click here.

  • Loading metrics

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia

  • Zheng Hu ,

    Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

  • Xiao-Fen Pan ,

    Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

  • Fu-Qun Wu ,

    Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

  • Li-Yuan Ma ,

    Contributed equally to this work with: Zheng Hu, Xiao-Fen Pan, Fu-Qun Wu, Li-Yuan Ma

    Affiliation State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Da-Peng Liu,

    Affiliation Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China

  • Ying Liu,

    Affiliations Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, University of Science and Technology of China, Hefei, China

  • Ting-Ting Feng,

    Affiliations Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, University of Science and Technology of China, Hefei, China

  • Fan-Yi Meng,

    Affiliation Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China

  • Xiao-Li Liu,

    Affiliation Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China

  • Qian-Li Jiang,

    Affiliation Department of Hematology, Nanfang Hospital Affiliated to Nanfang Medical University, Guangzhou, China

  • Xiao-Qin Chen,

    Affiliation Department of Hematology, the Cancer Hospital, Sun Yat-Sen University, Guangzhou, China

  • Jing-Lei Liu,

    Affiliations Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, University of Science and Technology of China, Hefei, China

  • Ping Liu,

    Affiliation State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Zhu Chen,

    Affiliation State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  • Sai-Juan Chen ,

    sjchen@stn.sh.cn (SJC); gbzhou@ioz.ac.cn (GBZ)

    Affiliation State Key Laboratory of Medical Genomics and Shanghai Institute of Hematology, Rui Jin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, China

  •  [ ... ],
  • Guang-Biao Zhou

    sjchen@stn.sh.cn (SJC); gbzhou@ioz.ac.cn (GBZ)

    Affiliations Laboratory of Molecular Target-Based Therapy for Cancer, Guangzhou Institute of Biomedicine and Health, Chinese Academy of Sciences, Guangzhou, China, Laboratory of Molecular Carcinogenesis and Targeted Therapy for Cancer, State Key Laboratory of Biomembrane and Membrane Biotechnology, Institute of Zoology, Chinese Academy of Sciences, Beijing, China

  • [ view all ]
  • [ view less ]

Viewed

Cited

Saved

Discussed

Powered by Altmetric
Questions or concerns about usage data? Please let us know.